NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis $0.66 0.00 (0.00%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$0.68 +0.02 (+3.44%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Milestone Pharmaceuticals Stock (NASDAQ:MIST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MIST alerts:Sign Up Key Stats Today's Range$0.65▼$0.7150-Day Range$0.64▼$1.2152-Week Range$0.63▼$3.06Volume6.45 million shsAverage Volume942,745 shsMarket Capitalization$82.44 millionP/E RatioN/ADividend YieldN/APrice Target$6.40Consensus RatingModerate Buy Company Overview Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s research is centered on treatments designed to provide rapid, patient-administered relief for episodic cardiovascular disorders. Milestone’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. The therapy has been developed primarily for the treatment of paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of abnormally rapid heart rate. By enabling administration outside of a hospital or clinical setting, etripamil is intended to give patients and healthcare providers an alternative to emergency-based treatment for certain acute episodes. Milestone Pharmaceuticals was founded in Canada and conducts its development activities in North America. The company is headquartered in Montreal, Quebec, and its shares trade on the Nasdaq Capital Market under the symbol MIST. Joseph Oliveto serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Milestone Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreMIST MarketRank™: 2.27171346103 of 5 starsMilestone Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 622nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMilestone Pharmaceuticals has a consensus price target of $6.40, representing about 866.5% upside from its current price of $0.66.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Milestone Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.83% of the float of Milestone Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 24.83, which indicates bearish sentiment.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 0.94%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentMilestone Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Milestone Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for MIST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.03% of the stock of Milestone Pharmaceuticals is held by insiders.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIST Stock News HeadlinesMilestone Pharmaceuticals (MIST) Set to Release Quarterly Earnings on Friday3 hours ago | americanbankingnews.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Now Rated "Moderate Buy" by Wall Street BrokeragesNovember 10 at 2:15 AM | americanbankingnews.comWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of AI." Musk's track record includes PayPal, Tesla and SpaceX. Tim Bohen has put the details of what he calls Musk's Mission X into a brand-new masterclass, free to watch with no credit card required. Viewers also receive a free ticker tied to Mission X. | StocksToTrade (Ad)Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 3, 2026 | globenewswire.comMilestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026November 3, 2026 | globenewswire.comNew Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior ...November 2, 2026 | markets.businessinsider.comNew Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter AblationNovember 2, 2026 | globenewswire.comMilestone Pharmaceuticals (MIST) Stock Sees Fair Value Falls As Analysts Reset Cardamyst ExpectationsOctober 23, 2026 | finance.yahoo.comSee More Headlines MIST Stock Analysis - Frequently Asked Questions How have MIST shares performed this year? Milestone Pharmaceuticals' stock was trading at $2.02 at the start of the year. Since then, MIST shares have decreased by 67.2% and is now trading at $0.6622. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.02. The firm had revenue of $559 thousand for the quarter, compared to the consensus estimate of $817 thousand. Read the conference call transcript. When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $82 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,500,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Milestone Pharmaceuticals' top institutional investors include RVW Wealth LLC (0.92%), Valeo Financial Advisors LLC (0.12%) and Pinnacle Wealth Planning Services Inc.. Insiders that own company stock include Joseph Oliveto, Lorenz Muller, David Bharucha and Jeffrey Edward Nelson. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include iBio (IBIO), Iovance Biotherapeutics (IOVA), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), NIO (NIO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/12/2026Today11/11/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MIST's financial health is in the Red zone, according to TradeSmith. MIST has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MIST CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees38Year Founded2005Price Target and Rating Average Price Target for Milestone Pharmaceuticals$6.40 High Price Target$8.00 Low Price Target$3.00 Potential Upside/Downside+866.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.06 million Net MarginsN/A Pretax Margin-3,657.42% Return on Equity-288.33% Return on Assets-58.27% Debt Debt-to-Equity Ratio3.25 Current Ratio8.13 Quick Ratio7.92 Sales & Book Value Annual Sales$2.34 million Price / Sales35.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book1.70Miscellaneous Outstanding Shares124,498,000Free Float118,236,000Market Cap$82.44 million OptionableOptionable Beta1.07 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:MIST) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThis 10.3% war bond closed once. It's finally open again.Todd Phillips has spent 30 years studying safe-money income. His test for real retirement income: can it promi...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
